Singh BNAntiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol81:3D, 1998
2.
Camm AJ, Yap Guan Yee.What should we expect from the next generation of antiarrhythmic drugs?J Cardiovasc Electrophysiol10:317, 1999
3.
Singh BNCurrent antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol10:283, 1999
4.
Singh BN (Ed). Approaches to controlling cardiac arrhythmias: Focus on amiodarone, the last 15 years . Am J Cardiol84: I R, 1999 (suppl)
5.
Wei Sun, Sarma JSM, Singh BNElectrophysiological effects of dronedarone (SR33589), a non-iodinated benzofuran derivative, in the rabbit heart: Comparison with amiodarone. Circulation100:2276, 1999
6.
Singh BN (Ed). Control cardiac arrhythmias with sotalol, a broad-spectrum anti-arrhythmic with beta-blocking effects and Class III activity. Am J Cardiol765:1A, 1990
7.
Singh BNSotalol: Current status and expanding indications. J Cardiovasc Pharmacol Therapeut4(1):59, 1999
8.
Murray KTIbutilide. Circulation97:493, 1998
9.
Torp-Pedersen C., Moller M., Bloch-Thomsen PE, et al, for the Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group.Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Eng J Med341:857, 1999
10.
Colatsky TJ , Follmer CH, Starmer CFChannel specificity in antiarrhythmic drug action. Mechanism of potassium-channel block and its role in suppressing and aggravating cardiac arrhythmias. Circ82:2235, 1990
11.
Fermini B., Jurkiewicz NK, Jow B.Use-dependent effect of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization block or delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol26:259, 1995
12.
Salata JJ, Brooks RRPharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovas Drug Rev15:137, 1997
13.
Singh BN, Mody FV, Lopez B., et al. Antiarrhythmic agents for atrial fibrillation:Focus on prolonging repolarization. Am J Cardiol84:161R, 1999
14.
Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: A dose-response study. J Am Coll Cardiol28:130, 1996
15.
Stambler BS , Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation . Circulation94:1613, 1996
16.
Bashir Y., Thomsen PB, Kingma J. et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol76:1040, 1995
17.
Echt DS, Lee JT, Murray KT, et al. A randomized, double-blind, placebo-controlled dose-ranging study of intravenous UK-68,798 (dofetilide) in patients with inducible sustained ventricular tachyarrhythmias. Circ84:714, 1991 (suppl) (abstr)
18.
Echt DS, Gremillion ST, Lee JT, et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol5:752. 1994
19.
Page RLEffects of Antiarrhythmic Medication on Implantable Cardioverter-Defibrillator Function. Am J Cardiol85:1481, 2000
20.
Pfizer Labs Data on file. Pfizer Inc, New York, NY.
21.
Carmeliet E.Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther262:809, 1992
22.
Jurkiewicz NK, Sanguinetti MCRate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res72:75, 1993
23.
Rasmussen HS , Allen MJ, Blackburn KJ, et al. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol20(suppl 12):S96, 1992
24.
Warmke J., Ganetzky B.A family of potassium channel genes related to EAG in Drosophila and mammals . Proc Natl Acad Sci U S A91:3438, 1994
25.
Veldkamp MW , van Ginneken Acg.Bouman LNSingle delayed rectifier channels in the membrane of rabbit ventricular myocytes. Circ Res72:865, 1993
26.
Veldkamp MW , van Ginneken AC, Opthof T., et al. Delayed rectifier channels in human ventricular myocytes. Circulation92:3497, 1995
27.
Kiehn J., Ficker E., Jarolimek W., et al. Mapping the block of dofetilide in the HERG potassium channel . Circ96(8S):425, 1997
28.
Gwilt M., Blackburn KJ, Burgess RA, et al. Electropharmacology of dofetilide, a new class III agent, in anesthetized dogs. Eur J Pharamcol215:237, 1992
29.
Sedgwick ML , Rasmussen HS, Cobbe SMEffects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol170:1432, 1992
30.
Yuan S., Wohlfart B., Rasmussen HS, et al. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. Eur Heart J15:514, 1994
31.
Demolis J-L. , Funck-Brentano C., Ropers J., et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circ94:1592, 1996
32.
Lande G., Maison-Blanche P., Fayn J., et al. Dynamic analysis of dofetilide-induced changes in ventricular repolarization. Clin Pharmacol Therapeut64:312, 1998
33.
Nemeth M., Varro A., Virag L., et al. Frequency-dependent cardiac electrophysiological effects of tedisamil: Comparison with quinidine and sotalol. J Cardiovasc Pharmacol Therapeut2:273, 1997
34.
Marschang H. , Brachmann J., Karolyi L., et al. Isoproterenol specitically modulates reverse rate-dependent effects of d,l-sotalol, d-sotalol, and dofetilide. J Cardiovasc Pharmacol35:443, 2000
35.
Gjini V., Korth M., Schreieck J., et al. Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies . J Cardiovasc Pharmacol28:314, 1996
36.
Murakawa Y. , Yamashita T., Kanese Y., et al. Do the effects of antiarrhythmic drugs on defibrillation efficacy vary among different shock waveforms? PACE21:1901, 1998
37.
Singh BNThe coming of age of the class III antiarrhythmic principle: Retrospective and future trends. Am J Cardiol78:17, 1996 (suppl)
38.
Echt DS, Black JN, Barbey JT et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: Sodium channel block and action potential prolongation . Circulation79:1106, 1989
39.
Chi L., Mu D., Driscoll EM, et al. Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol16:312, 1990
40.
Kou WH, Nelson SD, Lynch JJ, et al. Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. J Am Coll Cardiol9:359, 1987
41.
Sanguinetti MC, Jurkiewicz NKTwo components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol96:195, 1990
42.
Roden DMCurrent status of class III antiarrhythmic therapy. Am J Cardiol72:44B, 1993
43.
Yang T., Roden DMExtracellular potassium modulation of drug block of IKr: Implications for torsade de pointes and reverse use-dependence. Circulation93:407, 1996
44.
Williams ME , Gervino EV, Rosa DM, et al. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med312:823, 1985
45.
Kline RP, Cohen I., Falk R., et al. Activity-dependent extracellular K+ fluctuations in canine Purkinje fibres. Nature286:68, 1980
46.
Gjini V., Korth M., Schreieck J., et al. Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies . J Cardiovasc Pharmacol28:314, 1996
47.
Baskin EP, Lynch JJComparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031 and MK-499. J Cardiovasc Pharmacol24:199, 1994
48.
Singh BNThe coming of age of the class III antiarrhythmic principle: Retrospective and future trends. Am J Cardiol78:17, 1996
49.
Anyukhovsky EP, Sosunov EA, Rosen MRRegional differences in electrophysiological properties of epicardium, midmyocardium, and endocardium: In vitro and in vivo correlations. Circulation94:1981, 1996
50.
Anyukhovsky EP, Sosunov EA, Feinmark SJ, et al. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium, II: in vivo study. Circulation96:4019, 1997
51.
Bauer A., Ruediger B., Kirsten D., et al. Rate- and site-dependent effects of propafenone, dofetilide, and the new IKsblocking agent chromanol 293b on individual muscle layers of the intact canine heart. Circulation100:2184, 1999
52.
Mary-Rabine L., Albert A., Pham TD, et al. The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure . Circ Res52:188, 1983
53.
Kääb S. , Nuss HB, Chiamvimonvat N., et al. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure . Circ Res78:262, 1996
54.
Mukherjee R. , Hewett KW, Spinale FGMyocyte electrophysiological properties following the development of supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol27:1333, 1995
55.
Ouadid H., Albat B., Nargeot J.Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol25:282, 1995
56.
Le Grand B, Hatem S., Deroubaix E. et al. Depressed transient outward and calcium currents in dilated human atria. Cardiovasc Res28:548, 1994
57.
Koumi SI, Arentzen CE, Backer CL, et al. Alterations in muscarinic K+ channel response to acetylcholine and to G protein-mediated activation in atrial myocytes isolated from failing human hearts. Circ90:2213, 1994
58.
Van Wagoner DR, Pond AL, McCarthy PM, et al. Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation . Circ Res80:772, 1997
59.
Yue L., Feng J., Gaspo R., et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res81:512, 1997
60.
Li D., Melnyk P., Feng, J., et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation101:2631, 2000
61.
Li D., Benardeau A., Nattel S.Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation102:104, 2000
62.
Goette A., Honeycutt C., Langberg JLElectrical remodeling in atrial fibrillation: Time course and mechanisms . Circulation94:2968, 1996
63.
Gaspo R., Bosch RF, Talajic M., et al. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation96:4027, 1997
64.
Morillo CA, Klein GJ, Jones DL, et al. Chronic rapid atrial pacing: Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation91:1588, 1995
65.
Li D., Fareh S., Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation100:87, 1999
66.
Falk RH, Pollak A., Singh SN, et al, for Dofetilide Investigators.Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J. Am Coll Cardiol29:385, 1997
67.
Norgaard BL , Wachtell K., Christensen PD, et al, and the Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized. double-blind, placebo-controlled trial. Am Heart J137:1062, 1999
68.
Suttorp. MJ , Polak PE, van't Hof A., et al. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol69:417, 1992
69.
Lu HR, Remeysen P., Declerck F.Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs. J Cardiovasc Pharmacol26:132, 1995
70.
Black SC, Chi L., Mu DX, Lucchesi BRThe antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent . J Pharmacol Exp Ther258:416, 1991
71.
Andersen HR , Wiggers H., Knudsen LL, et al. Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia: A randomised study in pigs. Cardiovasc Res28:1635, 1994
72.
Gout B., Nichols AJ, Feuerstein GZ, et al. Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia. J Cardiovasc Pharmacol26:636, 1995
73.
Chen J., Xue Y., Eto K., et al. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. J Cardiovasc Pharmacol28:576, 1996
74.
Brachmann J. , Haverkamp W., Johns J., Zehender M., King-man HG, Wiecha J.The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia . Circulation86:265, 1995 (suppl) (abstr)
75.
Nademanee K. , Bailey WM, O'Neill G., et al. Electrophysiologic and hemodynamic effects of dofetilide in patients with depressed left ventricular function: a randomized, double-blind, placebo-controlled study. PACE21:867, 1998
76.
Sedgwick M. , Rasmussen HS, Walker D., et al. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug. Br J Clin Pharmacol31:515, 1991
77.
Le Coz F., Funck-Brentano C., Morell T., et al. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization . Clin Pharmacol Ther57:533, 1995
78.
Sedgewick ML , Dalrymple I., Rae APEffects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. Eur Heart J69:513, 1992
79.
Tham Tck, MacLennan BA, Burke MT et al. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK,68,798) in humans. J Cardiovasc Pharmacol21:507, 1993
80.
Greenbaum RA , Campbell TJ, Channer KS, et al. Conversion and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study. Circulation17:1-633, 1998 (suppl) (abstr)
81.
Benditt DG, Williams JH, Jin J. et al, for the dl-Sotalol Atrial Fibrillation/Flutter Study Group.Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and flutter: A dose-response study. Am J Cardiol84:270, 1999
82.
Edvardsson J., Huikuri H., Kenneback G., et al. Antiarrhythmic efficacy by a class III agent without beta-blockade in chronic atrial fibrillation: A double-blind randomized comparison of d,l-sotalol, d-sotalol and placebo: An European Multicenter Study. J Am Coll Cardiol27:46A, 1996 (suppl) (abstr)
83.
Roy D., Talajic M., Dorian P., et al. for the Canadian Trial of Atrial Fibrillation (CTAF) Investigators: Amiodarone to prevent recurrence of atrial fibrillation. N Eng J Med342:913, 2000
